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Abstract: 
 
Atrial fibrillation (AF) is a common arrhythmia. Better prevention and treatment of AF are needed to 
reduce AF-associated morbidity and mortality. There are several major mechanisms that cause AF in 
patients, including a genetic predisposition to develop AF. Genome-wide association studies (GWAS) 
have identified genetic variants associated with AF populations, with the strongest hits clustering on 
chromosome 4q25, close to the gene for the homeobox transcription factor PITX2. The effect of these 
common gene variants on cardiac PITX2 mRNA is currently under study. PITX2 protein regulates 
right-left differentiation of the embryonic heart, thorax, and aorta. PITX2 is expressed in the adult left 
atrium, but much less so in other heart chambers. Pitx2 deficiency results in electrical and structural 
  
 
remodeling, and impaired repair of the heart in murine models, all of which may influence AF 
through divergent mechanisms. PITX2 levels and SNPs on chromosome 4q25 may also be a predictor 
of the effectiveness of anti-arrhythmic drug therapy.  
 
Fahima Syeda is a Postdoctoral Research Fellow and Larissa Fabritz is a Reader (Associate Professor) 
in Cardiovascular Sciences at the Institute of Cardiovascular Sciences, University of Birmingham, 
United Kingdom. Larissa also sees patients as a Consultant in the Department of Cardiology at 
University Hospital Birmingham and is affiliated to the University of Muenster, Germany. Fahima 
gained her BSc at King’s College London and did a PhD in Cardiovascular Physiology at the University 
of Birmingham, where she studied cardiovascular adaptations to acute and chronic environmental 
change. Fahima currently uses electrophysiology and imaging techniques to identify mechanisms 
leading to atrial fibrillation, cardiomyopathies and sudden cardiac death. Our group studies the role 
of genetic and environmental factors in the development of these diseases and tests interventions in 
genetic models, helping to delineate new therapeutic targets for personalised treatment. 
 
 
 
Abbreviations 
AF- Atrial fibrillation 
GWAS- Genome-wide association studies 
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miRNA- microRNA 
PITX- Paired-like homeodomain transcription factor human and murine protein  
PITX- Paired-like homeodomain transcription factor human gene 
Pitx- Paired-like homeodomain transcription factor murine gene 
SNP- Single nucleotide polymorphism 
 
Introduction 
Atrial fibrillation (AF) affects two to three percent of the population in Europe and the US and the 
prevalence of AF is rising (Schnabel et al., 2015; Kirchhof et al., 2016). AF is a significant cause of 
death, stroke, dementia and reduced quality of life in the Western world and this issue is complicated 
by a lack of effective therapies. The treatment of AF has four different domains: treatment of 
underlying cardiovascular conditions, stroke prevention, rate control, and rhythm control. Even on 
optimal stroke prevention and rate control therapy, cardiovascular morbidity and mortality remains 
high (Marijon et al., 2013; Bassand et al., 2016). The success of rhythm control therapy is often 
unpredictable and recurrence is common. This outcome is partly attributable to our limited 
understanding of the underlying genetic causes of AF and the interaction of these causes with type of 
rhythm control therapy. Initial observations suggest that the haplotype of common AF-related variants 
modifies the outcome of antiarrhythmic therapy (Parvez et al., 2012; Huang & Darbar, 2016), 
suggesting that rhythm control therapy could benefit from precision and personalisation based on 
genomic information.  
 
AF has a heritable component 
AF appears to be familial in approximately 15% of early-onset AF without concomitant diseases and 
5% of all AF cases (Darbar et al., 2003), and a family history of early-onset AF increases overall AF 
risk (Fox et al., 2004). Linkage and functional studies have revealed the mutation of several 
potassium channels such as KCNQ1, KCNE2, KCNH2 in rare, monogenic families with a Mendelian 
pattern of AF inheritance (Chen et al., 2003; Yang et al., 2004; Hong et al., 2005; Xia et al., 2005). 
These gain or loss of function potassium channel mutations may account for some of the 
  
 
electrophysiological changes that promote AF, such as reduced wavelength or early 
afterdepolarisations, respectively. However, most AF patients do not harbour these rare genotypes 
with clear phenotypes, so the polygenic and multifactorial nature of AF is an important avenue of 
research. Therefore, transcriptional regulators with multiple effectors may play a significant role in 
familial AF caused by common genetic variants. 
  
Common gene variants associated with AF 
 Genome-wide association studies (GWAS), unbiased correlation studies designed to identify 
associations between allele frequencies and trait variation, have identified multiple loci that associate 
with AF (Gudbjartsson et al., 2007; Benjamin et al., 2009; Kaab et al., 2009; Ellinor et al., 2010; 
Schnabel et al., 2011; Ellinor et al., 2012). Initial GWAS identified two single nucleotide 
polymorphisms (rs2200733 and rs10033464) in European and Chinese populations (Gudbjartsson et 
al., 2007) on chromosome 4q25. Other loci exist on chromosome 16q22 within intron1 of the gene 
encoding ZHFX3 i.e. zinc finger homeobox protein 3 (Benjamin et al., 2009) and on chromosome 
1q21 on intron 1 of the gene for KCNN3 (involved in calcium-activated potassium channels (Ellinor 
et al., 2010)). Since these initial studies, a multitude of SNPs that associate with AF have been 
identified on chromosome 4q25. The gene variants on chromosome 4q25 are intergenic, but many of 
them are in a genomic “desert” approximately 150kb upstream from the gene for PITX2 (paired-like 
homeodomain transcription factor). 
 
The PITX gene family 
The PITX family of homeobox transcription factors consists of PITX1, PITX2 and PITX3, each of 
which have distinct and overlapping expression patterns, therefore functions, in different organs (Cox 
et al., 2002). All three members of the PITX family, predominantly PITX2 and PITX3 are expressed 
in the anterior segment of the eye. In humans, PITX2 mutations are associated with Axenfeld-Rieger 
syndrome and PITX3 mutations with congenital cataracts (Semina et al., 1998). PITX1 is also 
essential for hindlimb and pituitary development (Szeto et al., 1999), and PITX2 for tooth, heart, lung, 
and abdominal development in the mouse (Lin et al., 1999). 
 
Three PITX2 isoforms (PITX2a, PITX2b, and PITX2c), which are generated by alternative splicing 
and differential promoter usage of the PITX2 gene, are highly expressed in mice and humans during 
development (Schweickert et al., 2000). The PITX2d isoform, which exists in humans only, 
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suppresses the transcriptional activity of the PITX2a and PITX2c isoforms (Cox et al., 2002). The 
predominant cardiac isoform of PITX2 is PITX2c (Kirchhof et al., 2011).  
 
PITX2 promotes left right asymmetry  
PITX2 was initially described in the context of embryonic development of left-right asymmetry of 
internal organs: it is expressed in the left heart and gut of the mouse, chick, and xenopus, and its 
misexpression alters position and the twisting of organs (Ryan et al., 1998; Lin et al., 1999; Campione 
et al., 2001).  
 
The cardiac system shows left-right asymmetry, e.g. normal coordinated heartbeat is generated from 
the sinoatrial nodal pacemaker cells in the right atrium. The development of cardiac left-right specific 
characteristics such as the restriction of the sinoatrial node to the right atrium is critically dependent 
on asymmetrical organ morphogenesis (Mommersteeg et al., 2007; Galli et al., 2008). Cardiac left-
right asymmetry is subject to left-sided PITX2 expression (Galli et al., 2008; Tessari et al., 2008) 
particularly the PITX2C isoform (Schweickert et al., 2000; Kirchhof et al., 2011) through the lefty-
nodal programming pathway (Wang et al., 2010).   
 
PITX2-dependent gene expression in the adult heart 
Triggered by the GWAS study pointing to a possible role for PITX2 in AF, the role of PITX2 in the 
adult heart, in addition to its role in left-right asymmetry and cardiac development, has been 
investigated:  Pitx2c expression continues in the postnatal left atrium in mice and humans (Wang et 
al., 2010; Kahr et al., 2011; Kirchhof et al., 2011) and there is progressive loss of Pitx2c with age in 
mice (Wang et al., 2010). Thus, Pitx2c dysregulation has the potential to influence AF in adulthood 
and senescence. 
 
In AF, fast irregular atrial beats overtake the sinoatrial node, sometimes also resulting in ventricular 
arrhythmias. The origins of ectopic electrical activity are often in the pulmonary veins (Haissaguerre 
et al., 1998; Po et al., 2005) and if from the left atrium, then predominantly from the left atrial 
  
 
posterior wall (Sanders et al., 2005; Holmes et al., 2016). Given the crucial role of PITX2 in left-right 
asymmetry, it is probable that loss of PITX2 in some cases of heritable AF causes incomplete 
suppression of pacemaker activity in the left heart. This has been shown to be mediated by the loss of 
Shox2-silencing and increase in Hcn4 (Wang et al., 2010). 
 
PITX2 mRNA concentrations regulate atrial function  
Both under- and overexpression of PITX2 has been found to be associated with AF (Chinchilla et al., 
2011; Perez-Hernandez et al., 2016) in humans. The variability of PITX2 in AF patients suggests that 
there is a critical level of PITX2 for normal atrial function in the adult. We have recently shown a 
PITX2 mRNA gradient in AF patients requiring AF ablation. Hence, AF patients could be categorised 
according to PITX2 levels (Syeda et al., 2016). The mechanisms of AF promotion are diverse, and 
there are multiple pathways by which PITX2 could regulate arrhythmogenesis. This is unsurprising 
given that PITX2 is a transcription factor with multiple targets (Hjalt & Semina, 2005). Reduced Pitx2 
expression was associated with higher susceptibility to inducible atrial arrhythmias including AF in 
mice as observed by several groups (Wang et al., 2010; Chinchilla et al., 2011; Kirchhof et al., 2011). 
Shortened atrial action potential durations, a phenomenon facilitating reentry, were associated with 
Pitx2 deficiency (Kirchhof et al., 2011). 
 
Postnatal conditional deletion of all Pitx2 isoforms in the left atrium (Pitx2 CKO; achieved by using 
the muscle creatine kinase-Cre driver) generally resulted in upregulation of genes signifying that, on 
the whole, PITX2 represses translation. The Pitx2 CKO mouse had irregular resting heart rates and 
low amplitude P waves (Tao et al., 2014). The upregulation of genes associated with structural 
remodeling (e.g. integrin alpha 3 and 5) and cell-junction assembly (e.g. desmoplakin and 
connexin43) indicates that loss of Pitx2 may cause structural remodeling and damage to the 
intercalated disk (Tao et al., 2014). Prenatal atrial-specific deletion of all Pitx2 isoforms achieved by 
using a Nppa-Cre driver (NppaCre
+
Pitx2
-/-
) results in modest atrial enlargement and wall thinning 
during embryonic development (Chinchilla et al., 2011). Heterozygous deletion of isoform c-specific 
exon 4 resulting in a 40% reduced left atrial Pitx2c expression (Pitx2c
+/-
), in contrast, did not cause 
any obvious structural abnormalities (Kirchhof et al., 2011). 
 
Pitx2 overexpression can promote repair after myocardial injury. So it appears that there is a dynamic 
Pitx2 response to stress and metabolic changes (Tao et al., 2016). Cis-regulatory elements for the 
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transcription factor Tbx5 in regions analogous to the human PITX2 risk locus have also been found in 
the mouse. Postnatal deletion of Tbx5 led to Pitx2 reduction and caused atrial arrhythmias by action 
potential duration prolongation (Nadadur et al., 2016). Interestingly, inverse relationship between the 
effects of Tbx5 on some AF-relevant ion channel expression and the effects of Pitx2 on the same ion 
channels was observed (Tao et al., 2014) and the loss of Pitx2 reversed the pro-arrhythmic effects of 
the loss of Tbx5 because the loss of either facilitated AF through opposite mechanisms (Nadadur et 
al., 2016). 
 
Based on several animal models of Pitx2 loss, where haploinsufficiency of Pitx2 has resulted in a less 
severe phenotype than complete deletion, it can be deduced that there is a dose-dependent regulation 
of atrial function by Pitx2 in the adult left atrium (Wang et al., 2010; Kirchhof et al., 2011; Lozano-
Velasco et al., 2016). 
 
PITX2-dependent ion channel regulation 
Several potassium channel (Wang et al., 2010; Chinchilla et al., 2011; Kirchhof et al., 2011; Syeda et 
al., 2016) and calcium handling genes (Tao et al., 2014; Lozano-Velasco et al., 2016) are regulated by 
Pitx2, as seen in mutant Pitx2 models (Figure 1).  The action potential duration shortening observed in 
Pitx2c
+/-
 mice (Kirchhof et al., 2011) and depolarised resting membrane potential in NppaCre
+
Pitx2
-/-
 
mice and Pitx2c
+/-
 mice suggests that Pitx2 regulates the expression of several potassium channels 
contributing to atrial repolarisation and to the resting membrane potential. Indeed, in NppaCre
+
Pitx2
-/-
, expression of Kcnj2 is decreased (Chinchilla et al., 2011), which would cause a decrease in IK1, the 
primary determinant of the resting membrane potential. In Pitx2c
+/- 
mice, both the expression of 
TASK-2 and TASK- like background currents, contributors to the resting membrane potential, were 
reduced, though IK1 was not altered (Syeda et al., 2016).  
 
Non-protein targets of PITX2 
Multiple microRNAs (miRNAs), short non-coding strands of RNA that usually induce post-
transcriptional gene-silencing and fine-tune gene signaling during tissue development and 
homeostatic control (Beermann et al., 2016), are downstream from Pitx2 and involved in AF 
  
 
pathogenesis. Pitx2 expression co-localises with miR-17-92 cluster expression, and loss of Pitx2 
results in loss of multiple miRNAs that are encoded by miR-17-92 and its closely related homologue 
miR-106b-25. Mice deficient in these miRNA clusters share similar characteristics to Pitx2-deficient 
mice including induced arrhythmia susceptibility and dysregulation of Shox2 and Tbx3 (Wang et al., 
2014). The multiple miRNAs regulated by Pitx2 may partly explain how Pitx2 modulates several 
pathways potentially leading to AF (Li et al., 2016). 
  
Interactions between SNPs and transcription factors 
Several genes that are either associated with AF in patients who have common intronic or distal 
variants shown by GWAS or rare variants that directly cause AF as shown by linkage analysis, 
interact with PITX2. These include genes for TBX5 (Huang et al., 2015; Ma et al., 2016; Nadadur et 
al., 2016), HCN4 (Wang et al., 2010; Mahida & Ellinor, 2012), KCNN3 (Ellinor et al., 2010; Mahida 
& Ellinor, 2012; Lozano-Velasco et al., 2016), KCNJ2 (Xia et al., 2005; Chinchilla et al., 2011), 
CAV-1 (Mahida & Ellinor, 2012; Lozano-Velasco et al., 2016) and KCNQ1 (Chen et al., 2003; Wang 
et al., 2010), as seen in murine models. Thus, PITX2 potentially regulates AF through several genes 
already implicated in AF. 
 
It has also been observed that SNPs on different AF susceptibility loci (e.g. rs2200733 on 
chromosome 4q25 and rs2106261 on chromosome 16q22) interact with each other in AF (Huang et 
al., 2015) and Zfhx3 has been identified as a possible target for Pitx2 through CHIP-Seq analysis (Tao 
et al., 2014). Furthermore, the expression of Pitx2c mRNA positively correlates with ZFHX3 mRNA 
expression through miR-1 (Huang et al., 2015).  
 
Chromosome conformation capture studies have shown that there is long-range interaction between 
the risk locus at 4q25 and the PITX2c promoter (Aguirre et al., 2015), but beyond this finding, there is 
little information on how variants distal to PITX2 interact with PITX2 to cause AF. Interestingly, an 
AF-associated SNP proximal to PITX2 has been shown to regulate PITX2c expression in human stem 
cell-derived cardiomyocytes by regulating PITX2 enhancer activity (Ye et al., 2016).  
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Though the interaction between genetic variants close to PITX2 and PITX2 itself is not completely 
understood, the effects of the loss of PITX2 appear to converge with the presence of AF-associated 
SNPs. 
 
The potential to use PITX2 to personalise AF therapy 
Clinical observational studies have suggested that common AF risk alleles at chromosome 4q25 near 
PITX2 modify response to antiarrhythmic therapy in patients (Parvez et al., 2012). Low Pitx2 mRNA 
also improved the effectiveness of sodium channel blockers in a prospective experimental study 
(Syeda et al., 2016). PITX2 levels vary in AF patients (Syeda et al., 2016) and given the observation 
that loss of left atrial Pitx2 facilitates AF, it may be desirable to target those AF patients who have 
low PITX2 as a distinct population for therapy. There is however no clear relation between atrial 
tissue PITX2 mRNA levels and SNP haplotype of the common gene variants associated with AF in 
patients (Gore-Panter et al., 2014; Gore-Panter et al., 2016; Syeda et al., 2016).  
 
The current limited success of rhythm control therapy is thought to be due to heterogeneous drivers 
causing recurrent AF and modulating treatment response (Fabritz et al., 2016). Amongst the plethora 
of putative downstream targets of Pitx2, the resting membrane potential (Chinchilla et al., 2011; 
Syeda et al., 2016) is one that has been seen to be a good predictor of the sodium channel blocking 
effects of flecainide in isolated cells of human and mouse origin (Syeda et al., 2016). The resting 
membrane potential is also a good predictor of flecainide’s anti-arrhythmic effectiveness. By using a 
more precisely targeted approach, these observations of PITX2 dependent effects may help improve 
rhythm therapy in the future. 
Open questions regarding research into PITX2: 
1. A robust method for identification of patients with high and low atrial PITX2 levels is needed. 
Clearly, measuring PITX2 expression in atrial tissue of people who are not candidates for 
surgery is impracticable, so surrogate blood biomarkers of PITX could be used to subtype AF 
patient populations to bring about much-needed leaps in personalised predictions of both AF 
risk and response to therapy. Currently, the P wave in the ECG still remains the best 
biomarker for AF (Fabritz, 2016). 
  
 
2. Well-designed clinical trials to assess PITX2-dependence of the effectiveness of rhythm 
control therapy could help to reevaluate anti-arrhythmic drugs that have often been ineffective 
thus far. It is likely that these findings are not limited to PITX2 and the assessment of 
genotype-dependence on the effectiveness of other anti-arrhythmic drugs could be 
approached in this manner. 
3. Further exploration of the relevance of the resting membrane potential for antiarrhythmic 
drug therapy success in patients could be valuable. 
4. Determination of the major clinical types of AF reflecting different drivers of the arrhythmia 
– e.g. “early onset AF” as a proxy for genetic predisposition to AF. 
5. Characterisation of the interaction of atrial stressors that are often concurrent with AF, with 
different PITX2 expression levels could also guide the choice of antiarrhythmic drug. 
 
Conclusions 
Although the entire scope of the activities and interactions of PITX2 are yet to be elucidated, it is 
clear that PITX2 has important functions in the adult left atrium and there is evidence in animal 
models that reduced Pitx2 mRNA levels predispose atria to AF by changing its electrical function, 
whether by abnormal pacemaker activity or adverse electrical remodeling. While complete deletion of 
Pitx2 results in structural abnormalities, moderate reduction in atrial Pitx2 levels primarily alters 
electrical function of the atria, for example the resting membrane potential and ion channel function. 
Apparently, AF-associated SNPs on chromosome 4q25 in close proximity to the PITX2 gene do not 
directly relate to atrial PITX2 mRNA concentrations. Nonetheless, given emerging evidence that 
PITX2 not only contributes to AF but could be used to predict effectiveness of rhythm control therapy, 
further investigations into the key co-factors, regulators and targets of PITX2 could change the current 
strategies used to determine the choice of anti-arrhythmic drugs. 
Pitx2 alters the atrial resting membrane potential and thereby modulates the effectiveness of sodium 
channel blockers in mice. Reliable methods to identify alterations in PITX2 expression in humans may 
help to make an informed choice on antiarrhythmic drug therapy. 
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Abstract figure legend 
 
Figure 1. Reduced Pitx2 expression leads to proarrhythmic electrical remodelling. Several different 
murine models of Pitx2 downregulation have shown action potential shortening and a depolarised 
resting membrane, two established causes of arrhythmia. Alterations in calcium and potassium 
handling genes and TASK-like background currents have been postulated to contribute in different 
models. The type of electrical remodelling may be a predictor of the anti-arrhythmic effectiveness of 
rhythm control therapy. 
 
 
